Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Product Development topic
No spam. Unsubscribe anytime.
Oversight Committee approves eight product-development supplemental grants; authorizes advanced payments for awardees
Summary
The oversight committee approved eight supplemental product development awards (one taken separately because of a reported conflict) and authorized advance disbursement of funds for the approved companies under the General Appropriations Act provision cited by staff.
The CPRIT Oversight Committee approved eight supplemental product development awards recommended by the Program Integration Committee and authorized advance disbursement of grant funds to the awardees upon contract execution and tranche completion.
Chief Product Development Officer Ken Smith described the supplemental round, noting the cycle used previously funded companies to accelerate progress. The slate included companies working on monoclonal antibodies (OR502), AI radiation therapy planning (InForm AI), antibody programs for hematologic malignancies (Alterum Therapeutics), fluorescence-based fresh tissue imaging (Instapath), an improved rapamycin formulation for familial adenomatous polyposis (Rapamycin Holdings/eRAPA), commercial-scale production of ytterbium-176 (academic-to-private scale-up), a minimally invasive lung nodule excision device (PranaCore/METERCore), and cell-therapy manufacturing expansion (Resilience). Smith described clinical and manufacturing milestones tied to supplemental tranches.
The committee took a separate vote on DP250167; a recusal/conflict was noted for one oversight member on a different product-development application earlier in the meeting. The remaining seven supplemental grants were approved by committee vote.
Ms. Doyle notified the board that on May 16 she sought authority to disperse grant funds in advance to the eight companies. Pursuant to the General Appropriations Act, article 9, section 4.02(a), the committee voted to authorize CPRIT to make advanced payments upon contract execution and successful completion of tranches for the approved supplemental grants.
Committee members discussed the review process, commercialization milestones, and the use of equity arrangements for certain tranches (OncoResponse example discussed in detail). Staff described the product-development peer review process and costs for peer review and due diligence; members discussed cycle frequency and possible cost savings by concentrating larger annual cycles or using follow-on supplemental cycles for existing portfolio companies.
